<DOC>
	<DOCNO>NCT01536938</DOCNO>
	<brief_summary>The purpose study investigate whether LEO 90100 , calcipotriol betamethasone effective treatment psoriasis vulgaris .</brief_summary>
	<brief_title>LEO 90100 Treatment Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Signed date informed consent obtain prior trial related activity ( include washout period ) . Age 18 year Either sex Any race ethnicity All skin type Females childbearing potential must negative pregnancy test Day 0 ( Visit 1 ) . Females childbearing potential must agree use highly effective method birth control study . A highly effective method birth control define one result low failure rate ( le 1 % per year ) . Able communicate investigator understand comply requirement study . Systemic treatment biological therapy , whether market , possible effect psoriasis vulgaris within follow time period prior randomisation : etanercept within 4 week prior randomisation adalimumab , alefacept , infliximab within 8 week prior randomisation ustekinumab within 16 week prior randomisation product 4 weeks/5 halflives ( whichever longer ) Systemic treatment therapy possible effect psoriasis vulgaris ( e.g. , corticosteroid , retinoids , methotrexate , ciclosporin immunosuppressant ) within 4 week prior randomisation . Subjects receive treatment nonmarketed drug substance ( i.e . drug yet make available clinical use follow registration ) within 4 weeks/5 halflives ( whichever longer ) prior randomisation . PUVA therapy within 4 week prior randomisation . UVB therapy within 2 week prior randomisation . Planned excessive exposure area ( ) treat study medication either natural artificial sunlight ( include tan booth , sun lamp , etc . ) study . Planned initiation , change , concomitant medication could affect psoriasis vulgaris ( e.g . beta blocker , antimalarial drug , lithium , ACE inhibitor ) study . Current diagnosis guttate , erythrodermic , exfoliative pustular psoriasis . Subjects follow condition present treatment area : viral ( e.g . herpes varicella ) lesion skin , fungal bacterial skin infection , parasitic infection , skin manifestation relation syphilis tuberculosis , acne vulgaris , atrophic skin , stria atrophicae , fragility skin vein , icthyosis , ulcer wound . Other inflammatory skin disorder ( e.g . seborrhoeic dermatitis contact dermatitis ) treatment area may confound evaluation psoriasis vulgaris . Known suspected disorder calcium metabolism associate hypercalcaemia . Known suspect severe renal insufficiency severe hepatic disorder . Known suspect hypersensitivity component ( ) investigational product . Current participation interventional clinical study . Previously randomise study . Females pregnant , wish become pregnant study , breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>